Groundbreaking £1.65m gene-editing therapy approved for NHS use offers hope to severe sickle cell patients

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those of African or Caribbean descent, causing symptoms such as intense pain, life-threatening infections, and anaemia.